Johnson & Johnson announced Tuesday that its second dose of the COVID-19 vaccine increases protection by 94% after two months of receiving the initial shot.
The Phase 3 study found that Johnson & Johnson’s two-month booster shot gives 100% protection against severe cases of COVID-19, and 94% against moderate symptomatic cases in the U.S., according to a company press release. The current single-dose vaccine is 75% effective.
“Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations. Additionally, our Phase 3 trial data further confirm protection against COVID-19-related death,” Mathai Mammen, global head of research and development at Johnson and Johnson, said in the press release.
📍BREAKING—At last—new data on 2-doses of Johnson & Johnson’s #vaccine (doses 56 days apart) is 94% effective against symptomatic #COVID19, thus comparable to Moderna/Pfizer. And 100% effective against severe COVID. Booster for 1 dose works well too. 🧵https://t.co/3nPkodOjuG pic.twitter.com/DizjWt9NYX
— Eric Feigl-Ding (@DrEricDing) September 21, 2021
“We now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly,” Paul Stoffels, chief scientific officer at Johnson and Johnson, said in the press release.
The side effects of the booster are reported to be similar to those experienced with the single shot, according to the press release. Johnson & Johnson’s vaccine is currently the only single-shot jab offered in the U.S., while Pfizer and Moderna require two does.
Johnson & Johnson’s announcement comes after the Food and Drug Administration voted against approving Pfizer’s COVID-19 booster shot for U.S. citizens ages 16 and older. The panel approved the third shot for adults over the age of 65.
Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact [email protected]